Supplemental Figure S5. Cilostazol strongly inhibit stemness and metastasis in vitro and in vivo. (A) The IC50 of MDA-MB-231 and T-47D cells treated with Cilostazol in 24, 48, 72 hours. (B) Cell viability assay of LO2 cell, HepG2 cell, A549 cell, HeLa
cell and H9c2 treated with cilostazol at 24h, 48h, 72h. (C) The IC50 of LO2, HepG2, A549, HeLa and H9c2 cells treated with cilostazol in 24, 48, 72 hours. (D) The comparison the IC50s of MDA-MB-231 and T-47D cells treatment with cilostazol to PDE3A knockdown. (E-F) Metastatic analysis for T-47D and MDA-MB-231 breast cancer cells treated with cilostazol by wound healing (E) and transwell (F) assay. (G-H) PDE3A and stemness markers OCT4, SOX2, Nanog expression by WB and qRT-RCR assay. (I) The tumor mass of mice treated with cilostazol on concertation 0, 25,50,75mg/Kg (n=5 per group). (J) PDE3A, OCT4 and CCDC88A expression in mice tumor tissue when treated with cilostazol by IHC staining.